Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTUARY extension study of amlitelimab in moderate-to-severe atopic dermatitis
jRCT2061240027Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants who maintain clinical response at Week 48. Started Jul 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061240027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240027.